MoonLake Immunotherapeuti... (MLTX)
38.33
1.36 (3.68%)
At close: Apr 17, 2025, 3:59 PM
38.99
1.74%
After-hours: Apr 17, 2025, 04:55 PM EDT
3.68% (1D)
| Bid | 28 |
| Market Cap | 2.43B |
| Revenue (ttm) | 101.85K |
| Net Income (ttm) | -118.94M |
| EPS (ttm) | -1.89 |
| PE Ratio (ttm) | -20.28 |
| Forward PE | -10.36 |
| Analyst | Buy |
| Ask | 40 |
| Volume | 245,225 |
| Avg. Volume (20D) | 429,875 |
| Open | 37.33 |
| Previous Close | 36.97 |
| Day's Range | 36.90 - 38.37 |
| 52-Week Range | 31.42 - 58.26 |
| Beta | 1.31 |
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 20, 2020
Employees 100
Stock Exchange NASDAQ
Ticker Symbol MLTX
Website https://www.moonlaketx.com
Analyst Forecast
According to 8 analyst ratings, the average rating for MLTX stock is "Buy." The 12-month stock price forecast is $73, which is an increase of 90.48% from the latest price.
Stock Forecasts1 month ago
+2.53%
MoonLake Immunotherapeutics shares are trading hig...
Unlock content with
Pro Subscription
3 months ago
+5.64%
MoonLake Immunotherapeutics shares are trading higher after Goldman Sachs upgraded the stock from Neutral to Buy and raised its price target from $62 to $82.
